Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NUVB 
Nuvation Bio Inc (NUVB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: NUVB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.5
1 Year Target Price $7.5
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 16.29% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.08B USD | Price to earnings Ratio - | 1Y Target Price 7.5 |
Price to earnings Ratio - | 1Y Target Price 7.5 | ||
Volume (30-day avg) 7 | Beta 1.37 | 52 Weeks Range 1.54 - 4.09 | Updated Date 09/16/2025 |
52 Weeks Range 1.54 - 4.09 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1315.72% |
Management Effectiveness
Return on Assets (TTM) 20.17% | Return on Equity (TTM) -44.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 524778347 | Price to Sales(TTM) 75.11 |
Enterprise Value 524778347 | Price to Sales(TTM) 75.11 | ||
Enterprise Value to Revenue 36.56 | Enterprise Value to EBITDA 2.23 | Shares Outstanding 341272992 | Shares Floating 231047778 |
Shares Outstanding 341272992 | Shares Floating 231047778 | ||
Percent Insiders 19.03 | Percent Institutions 66.74 |
Upturn AI SWOT
Nuvation Bio Inc
Company Overview
History and Background
Nuvation Bio Inc. was founded in 2018 by David Hung. It focuses on developing therapies for unmet medical needs, particularly in oncology. The company aims to in-license and develop promising drug candidates.
Core Business Areas
- Oncology Drug Development: Focuses on developing therapies for various cancers, including both solid tumors and hematologic malignancies.
Leadership and Structure
David Hung is the founder and CEO. The company has a board of directors and a management team overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- NUV-868: A BDCR-resistant and brain-penetrant inhibitor of HER2. It is in clinical trials for HER2-altered solid tumors. There is currently no significant market share for this product as it's in development stage. Competitors include companies developing other HER2 inhibitors, such as AstraZeneca (AZN) and Roche (RHHBY).
- NUV-1511: A novel oral selective replication-competent oncolytic virus engineered to selectively replicate within cancer cells, leading to tumor lysis and immune activation. It is in clinical trials for advanced solid tumors. There is currently no significant market share for this product as it's in development stage. Competitors include companies developing other oncolytic viruses, such as Amgen (AMGN).
Market Dynamics
Industry Overview
The oncology market is a large and rapidly growing market driven by increasing cancer incidence and improved treatment options. There is intense competition among pharmaceutical and biotechnology companies.
Positioning
Nuvation Bio aims to differentiate itself by focusing on in-licensing and developing novel therapies that address unmet needs in specific cancer subtypes. Its competitive advantage lies in its focused approach and experienced leadership team.
Total Addressable Market (TAM)
The global oncology market is projected to reach trillions of dollars. Nuvation Bio is positioned to capture a portion of this market by developing targeted therapies for specific cancer indications.
Upturn SWOT Analysis
Strengths
- Experienced leadership team
- Focused development strategy
- Promising drug candidates in pipeline
- Strong financial backing
Weaknesses
- Limited number of products in pipeline
- Reliance on successful clinical trials
- High cash burn rate
- Relatively new company
Opportunities
- Expansion of product pipeline through in-licensing
- Positive clinical trial results
- Strategic partnerships with larger pharmaceutical companies
- Approval of drug candidates by regulatory agencies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- AZN
- RHHBY
- AMGN
- MRTX
Competitive Landscape
Nuvation Bio faces intense competition from established pharmaceutical companies with larger pipelines and greater resources. Its success depends on its ability to differentiate its therapies and execute its clinical development strategy.
Growth Trajectory and Initiatives
Historical Growth: Nuvation Bio's growth is primarily reflected in the advancement of its clinical pipeline. No revenue to date.
Future Projections: Future growth depends on the successful development and commercialization of its drug candidates. Analyst estimates vary widely depending on clinical trial outcomes.
Recent Initiatives: Advancing NUV-868 and NUV-1511 through clinical trials, exploring new in-licensing opportunities.
Summary
Nuvation Bio is a clinical-stage biopharmaceutical company with promising oncology assets. Its success is contingent upon positive clinical trial results and regulatory approvals. While the company has a strong leadership team and financial backing, it faces significant competition and inherent risks associated with drug development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nuvation Bio Inc
Exchange NYSE | Headquaters New York, NY, United States | ||
IPO Launch date 2020-08-24 | Founder, President, CEO & Chairman Dr. David T. Hung M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 278 | Website https://www.nuvationbio.com |
Full time employees 278 | Website https://www.nuvationbio.com | ||
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.